Clinical trial
Preservation of Renal Function in Liver Transplant Recipients With Certican…
NCT00378014 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00378014 |
|---|---|
| Title | Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy |
| Official title | Presentation of Renal Function in Liver Transplant Recipients With Certican Therapy: PROTECT Study A Twelve-month, Multicenter, Randomized, Open-label Study of Safety, Tolerability and Efficacy of Certican-based Regimen Versus Calcineurin Inhibitor-based Regimen in de Novo Liver Transplant… |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Liver Transplantation |
| Intervention type | Drug |
| Interventions | everolimus, basiliximab, CNI |
| Enrollment | 276 |
| Start date | Aug 1, 2006 |
| Primary completion | Jan 1, 2013 |
| Completion | Jan 1, 2013 |
| First posted | Sep 19, 2006 |
| Last update posted | Feb 6, 2015 |
| Countries | Austria, Germany, Netherlands, Switzerland |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: